Carmine Stengone's most recent trade in Contineum Therapeutics Inc. - Ordinary Shares - Class A was a trade of 4,400 Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 24, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Contineum Therapeutics Inc (Class A) | Carmine Stengone | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2026 | 4,400 | 123,617 | - | - | Stock Option (right to buy) | |
| Contineum Therapeutics Inc (Class A) | Carmine Stengone | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 16.02 per share. | 24 Feb 2026 | 4,400 | 14,954 | - | 16.0 | 70,486 | Class A Common Stock |
| Contineum Therapeutics Inc (Class A) | Carmine Stengone | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.26 per share. | 24 Feb 2026 | 4,400 | 19,354 | - | 1.3 | 5,544 | Class A Common Stock |
| Contineum Therapeutics Inc (Class A) | Carmine Stengone | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2026 | 2,700 | 120,917 | - | - | Stock Option (right to buy) | |
| Contineum Therapeutics Inc (Class A) | Carmine Stengone | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 16.02 per share. | 24 Feb 2026 | 2,700 | 14,954 | - | 16.0 | 43,242 | Class A Common Stock |
| Contineum Therapeutics Inc (Class A) | Carmine Stengone | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.26 per share. | 24 Feb 2026 | 2,700 | 17,654 | - | 1.3 | 3,402 | Class A Common Stock |
| Contineum Therapeutics Inc (Class A) | Carmine Stengone | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 16.00 per share. | 11 Feb 2026 | 400 | 14,954 | - | 16 | 6,400 | Class A Common Stock |
| Contineum Therapeutics Inc (Class A) | Carmine Stengone | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2026 | 400 | 128,017 | - | - | Stock Option (right to buy) | |
| Contineum Therapeutics Inc (Class A) | Carmine Stengone | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.26 per share. | 11 Feb 2026 | 400 | 15,354 | - | 1.3 | 504 | Class A Common Stock |
| Contineum Therapeutics Inc (Class A) | Carmine Stengone | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2026 | 445,000 | 445,000 | - | - | Stock Option (right to buy) | |
| Kiora Pharma Inc | Carmine Stengone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Contineum Therapeutics Inc (Class A) | Carmine Stengone | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 300,000 | 300,000 | - | - | Stock Option (right to buy) | |
| Kiora Pharma Inc | Carmine Stengone | Director | Purchase of securities on an exchange or from another person at price $ 3.68 per share. | 11 Sep 2024 | 1,250 | 1,250 (0%) | 0% | 3.7 | 4,600 | Common Stock |
| Kiora Pharma Inc | Carmine Stengone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 1,778 | 1,778 | - | - | Stock Option (right to buy) | |
| Contineum Therapeutics Inc (Class A) | Carmine Stengone | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2024 | 285,000 | 285,000 | - | - | Stock Option (right to buy) |